Analysts Set Agile Therapeutics, Inc. (AGRX) Target Price at $10.00
Agile Therapeutics, Inc. (NASDAQ:AGRX) has received an average recommendation of “Buy” from the eight analysts that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $10.00.
AGRX has been the subject of several analyst reports. Noble Financial reissued a “buy” rating on shares of Agile Therapeutics in a research note on Wednesday, June 14th. Janney Montgomery Scott reissued a “buy” rating and set a $13.00 target price on shares of Agile Therapeutics in a report on Thursday. HC Wainwright began coverage on Agile Therapeutics in a report on Wednesday, July 19th. They set a “buy” rating and a $10.00 target price for the company. Royal Bank Of Canada set a $8.00 target price on Agile Therapeutics and gave the stock a “buy” rating in a report on Sunday, July 16th. Finally, ValuEngine upgraded Agile Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, July 8th.
Shares of Agile Therapeutics (AGRX) traded up 2.36% on Wednesday, reaching $3.47. 526,018 shares of the company were exchanged. Agile Therapeutics has a 12 month low of $1.82 and a 12 month high of $7.95. The stock’s market capitalization is $99.96 million. The stock has a 50 day moving average price of $3.74 and a 200-day moving average price of $3.40.
Agile Therapeutics (NASDAQ:AGRX) last issued its quarterly earnings results on Friday, July 28th. The specialty pharmaceutical company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.02. During the same quarter in the prior year, the firm earned ($0.29) EPS. On average, equities analysts expect that Agile Therapeutics will post ($1.03) EPS for the current fiscal year.
In other news, Chairman Alfred Altomari bought 10,000 shares of the stock in a transaction dated Friday, August 25th. The shares were bought at an average cost of $3.34 per share, with a total value of $33,400.00. Following the completion of the transaction, the chairman now directly owns 161,587 shares of the company’s stock, valued at $539,700.58. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 3.50% of the stock is owned by corporate insiders.
A number of institutional investors have recently made changes to their positions in the stock. Susquehanna International Group LLP bought a new position in Agile Therapeutics in the 2nd quarter valued at $205,000. Royal Bank of Canada lifted its position in shares of Agile Therapeutics by 608.0% during the 2nd quarter. Royal Bank of Canada now owns 32,497 shares of the specialty pharmaceutical company’s stock valued at $122,000 after buying an additional 27,907 shares during the last quarter. Goldman Sachs Group Inc. purchased a new position in shares of Agile Therapeutics during the 2nd quarter valued at $309,000. Dimensional Fund Advisors LP lifted its position in shares of Agile Therapeutics by 604.2% during the 2nd quarter. Dimensional Fund Advisors LP now owns 95,820 shares of the specialty pharmaceutical company’s stock valued at $359,000 after buying an additional 82,213 shares during the last quarter. Finally, Franklin Resources Inc. lifted its position in shares of Agile Therapeutics by 39.2% during the 2nd quarter. Franklin Resources Inc. now owns 2,772,200 shares of the specialty pharmaceutical company’s stock valued at $10,396,000 after buying an additional 780,578 shares during the last quarter. Institutional investors and hedge funds own 67.59% of the company’s stock.
Agile Therapeutics Company Profile
Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.
Receive News & Stock Ratings for Agile Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics Inc. and related stocks with our FREE daily email newsletter.